Genentech Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Nov 29, 2022 Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication Aug 24, 2022 MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape Premium Aug 24, 2022 Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Jul 27, 2022 Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jun 30, 2022 Analysis of Tumor Mutation, Treatment Data Across Cancers Points to Predictive Biomarkers Jun 6, 2022 Vectibix Outperforms Avastin in First-Line RAS-Wildtype Left-Sided Colorectal Cancer Premium May 26, 2022 UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients Premium May 25, 2022 NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold May 13, 2022 FDA Asks Industry to Come Up With Plans to Address Diversity in Drug, Diagnostic Trials May 11, 2022 Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials Mar 8, 2022 UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC Feb 25, 2022 NICE Recommends Seagen's Tukysa for Advanced HER2-Positive Breast Cancer in England Feb 16, 2022 Rozlytrek Studies Show Durable Responses in Patients With Brain Metastases Premium Jan 7, 2022 Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps Dec 3, 2021 FDA Approves Genentech's Rituxan, Chemo for CD20-Positive Pediatric Leukemia, Lymphoma Patients Oct 15, 2021 FDA Approves Genentech's Tecentriq as Adjuvant Treatment for PD-L1-Expressing NSCLC Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma